| Product Name | Entrectinib - API |
| Product Code | DA-E073-01 |
| Chemical name | Entrectinib |
| Synonyms | N-(5-(3,5-Difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzamide; N-[5-[(3,5-Difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]benzamide; |
| Impurity | NA |
| CAS Number | 1108743-60-7 |
| Alternate CAS # | NA |
| Molecular form | C31H34F2N6O2 |
| Appearance | NA |
| Melting Point | NA |
| Mol. Weight | 560.65 |
| Storage | 2-8°C Refrigerator |
| Solubility | NA |
| Stability | NA |
| Category | pharmaceutical standards,impurities,intermediates,metabolites,fine chemicals |
| Boiling Point | NA |
| Applications | Entrectinib, also known as RXDX-101 and NMS-E628, is an oral small molecule inhibitor of TrkA, TrkB and TrkC, as well as ROS1 and ALK, with high potency and selectivity. RXDX-101 has demonstrated potent pharmacological activity in preclinical studies and has the potential to be first-in-class against the Trk family of kises. PXDX-101 has been well tolerated in patients with advanced solid tumors. PXDX-101 is currently in clinical trials, and is being developed by Ignyta. |
| Dangerous Goods Info | NA |
| References | NA |
| Extra Notes | NA |
| Documents (MSDS) | No Data Available |
| Keywords | NA |
